HB 1237 amends Pennsylvania law to expand problem-solving courts, such as drug, mental health, and veterans courts, in courts of common pleas. It allows these courts to be established using available funds and creates a Statewide Coordinator to help with funding, coordination, and evaluation of such programs. The bill also changes sentencing rules: for technical probation violations (like missing a meeting), courts must consider a defendant’s employment status and may allow up to 30 days of confinement to enter a problem-solving court. This directly affects defendants on probation who might be referred to treatment programs instead of jail, as well as the courts administering these programs. The law takes effect in 60 days.
SB 715 extends the expiration date of Pennsylvania's Rare Disease Advisory Council from June 30, 2025, to June 30, 2028. This procedural bill directly affects the council, which advises state departments on rare disease issues, and the departments it collaborates with (Health, Insurance, Human Services, Education). The key provision simply changes the expiration date in the 2017 law without altering the council's structure or duties. This extension provides continued operation of the council for an additional three years.
HB 931 would require applicants for most public benefits in Pennsylvania to provide proof of lawful presence in the United States, such as housing assistance, health programs, and non-excluded food aid. Applicants must submit identification and documentation confirming legal status when applying, but excludes specific programs like SNAP (food stamps) and refugee services as defined by federal law. The requirement does not apply to refugees, permanent residents, or nonimmigrants under certain visa categories. This bill affects individuals seeking state and local public benefits not covered by the exclusions.
HB 269 amends Pennsylvania's Controlled Substance Act to improve access to overdose response information. It requires the Department of Health to develop free online training materials, posters, and pamphlets about recognizing opioid overdoses and using reversal medications (like naloxone), with the materials available in multiple languages upon request. Specific public entities - including Commonwealth agencies, transit authorities, municipalities, and local transportation organizations - must display the poster in conspicuous public locations, such as bathrooms or lobbies. The Department covers all printing and distribution costs, and entities already displaying equivalent materials may substitute them with prior notice. This bill focuses on education and resource accessibility, not changing drug laws or medication access.
HB 1334 allocates funding from the Workmen's Compensation Administration Fund to Pennsylvania's Department of Labor and Industry, Department of Community and Economic Development, and the Office of Small Business Advocate. It covers expenses for administering the Workers' Compensation Act, Pennsylvania Occupational Disease Act, and the Small Business Advocate program for fiscal year 2025-2026, including payments for unpaid bills from the prior fiscal year. The bill directly affects state agencies responsible for worker compensation, occupational disease claims, and small business support services. This is a routine appropriations measure to ensure ongoing operations of these programs, not a policy change. The bill was signed into law as Act No. 3A of 2025 on June 27, 2025.
HB 2041 amends Pennsylvania's Childhood Blood Lead Test Act to require health care practitioners to ensure children receive at least one blood lead test by 12 months of age and a second test by 24 months of age, with additional testing mandated between 24 and 72 months if not tested by age 2. The bill also requires blood lead testing for pregnant women who have at least one identified lead exposure risk factor. It clarifies that health insurance must cover these tests without cost-sharing, as defined in the bill. This law directly affects children under 72 months, pregnant women, and health care providers in Pennsylvania.
HB 1757 creates a voluntary Pennsylvania firefighter cancer registry managed by the Department of Health. It requires collecting anonymized data from firefighters, including fire incident types, work history, health information, and demographics, to link with existing cancer registry data. The registry aims to identify cancer trends and regional disparities among firefighters, with annual reports to the Governor and legislature containing findings and recommendations. All data remains confidential and cannot be used in court or for disciplinary actions. The registry will also make de-identified data available for public research without fees.
HB 409 amends Pennsylvania's Patient Test Result Information Act to require healthcare providers to give patients written notice at the time of diagnostic imaging services (like X-rays, MRIs, and ultrasounds) about how to access their results, including online portals or mail (with a possible fee for mailing). It also mandates a follow-up notice within 20 days if a significant abnormality is found, including details like the test date and ordering doctor's name, unless exceptions apply. Exceptions include routine obstetrical ultrasounds, inpatient or emergency care, diagnostic radiographs (X-rays), and patients with chronic conditions who were previously notified. This bill directly affects patients receiving diagnostic imaging and the healthcare facilities performing these services.
This Pennsylvania House resolution (HR 160) urges Congress to amend the PACT Act to include veterans exposed to toxic substances at Camp Carroll military base in South Korea. It specifically seeks to extend the PACT Act's health benefits - which currently cover veterans exposed to toxins at other sites - to veterans who served at Camp Carroll during the Vietnam War era and developed related illnesses like cancer or diabetes. The resolution cites a 2011 report confirming chemical burial at Camp Carroll and notes these veterans remain excluded from PACT Act benefits despite documented health impacts. It does not create new law but formally requests congressional action to correct this exclusion.
This bill establishes the Opioid Reparation and Accountability Fund, which will receive fees from opioid manufacturers and distributors, and creates the Opiate Epidemic Response Advisory Council. It requires opioid manufacturers/distributors to obtain licenses and pay $27,500 annually for licenses (with $2,500 for non-opioid drugs), plus an additional annual fee if they distribute over 2 million opioid units. The Department of Health, Human Services, and Drug and Alcohol Programs must implement new reporting requirements, manage the fund, and coordinate with the advisory council. The fund will support community programs addressing the opioid crisis, directly affecting opioid manufacturers, distributors, and state agencies responsible for oversight.
